Skip to main content
OpenTrials
Completed

NCT Number: NCT03552068

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

Noradrenergic system is involved in impulsivity in the general population and is altered in Parkinson's disease (PD) in the early stages of the disease. Thus, targeting this system could be of interest in impulse control disorder (ICD). Acting on the noradrenergic system is possible using clonidine, an α2 adrenergic agonist largely used in hypertension treatment and that induces a decrease of NADR release. Thus, our aim is to conduct a proof of concept study evaluating the efficacy and safety of clonidine on ICD in PD. This study is a multicenter, randomized, double-blind, placebo-controlled in parallel group clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Disruptive, Impulse Control, and Conduct Disorders Mental Disorders Movement Disorders Mpulse Control Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hospices Civils de Lyon

Bron, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with PD according to MDS (movement disorders society) criteria for at least one year
  • Patients with ICD with a QUIP-RS score ≥10 and/or at least one of the sub-scores in the following range: Pathological gambling between >6 and 12; Pathological gambling between >8 and 12; Hypersexuality between > 8 and 12; Eating between > 7 and 12. The use of "lower" margins will guarantee that patients will present behavioral disturbances severe enough to justify clonidine treatment. On the other hand, the use of "upper" margins will guarantee that the patients included in the trial will not suffer from ICD too severe to ethically participate to a placebo controlled study.
  • Weight between 40 and 95kg
  • Stable antiparkinsonian medication since at least 2 months before randomization and medication supposed to remain stable during the study
  • ICD onset after Parkinson's disease onset and after initiation of dopaminergic drugs
  • No signs of dementia (Montreal Cognitive Assessment, MOCA >20);
  • No lactose intolerance which may compromise the tolerance of the placebo;
  • Patients with health insurance
  • Patients without judicial protection measure except directly linked to ICD
  • For women of childbearing potential, an effective contraception method for at least 2 months before randomization (as implants or oral oestro-progestative contraceptives), condom use for men during the study. βHCG dosage in urine should be negative at randomization for women.

Exclusion criteria

Patients with major depression (BDI >19);

  • Patients with another parkinsonian syndrome (Parkinson "plus" or vascular Parkinsonism)
  • Orthostatic hypotension
  • Patients with swallowing disorders that may prevent oral medication,
  • Contraindication to clonidine: Hypersensibility; Severe bradyarythmia due to a cardiac disease
  • Patients receiving a treatment potentially interacting with clonidine
  • Patients with Raynaud's disease or obliterating thromboangiitis
  • Patients With Heart failure or severe coronary artery disease
  • Patients with a drug treatment having a potential interaction with clonidine (see list, appendix 2);
  • Presence of renal failure (Cockcroft-Gault at inclusion visit<30 ml/min/1,73m2);
  • Patients with a present or past history of addiction (apart ICD) or with a substance abuse (except Tabaco)
  • Pregnant or lactating women
  • Already participating in another biomedical research project

Treatment and study plan

Placebo

Drug

Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.

Medication: placebo twice a day (in the morning and evening).

Clonidine

Drug

Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).

Primary outcomes

  1. QUIP-RS (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease - Rating Scale)

    Time frame: at 8 weeks

    Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the eighth week under clonidine.

    Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the eighth week under clonidine.

    Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the eighth week under clonidine.

Secondary outcomes

  1. MDS-UPDRS

    Time frame: at 4 and 8 weeks

    The Movement Disorder Society Unified Parkinson Disease Rating

  2. STAI

    Time frame: at 4 and 8 weeks

    State-Trait Anxiety Index

  3. BDI II

    Time frame: at 4 and 8 weeks

    Beck Depression Inventory II It is a self-administered questionnaire each of them using a four-point ordinal scoring system. For the summary index the scores were standardized from 1 to 40, so that higher scores indicate higher depression.

  4. ECMP scores

    Time frame: at 4 and 8 weeks

    Behavior evaluation of Parkinson's patients It is a self-administered questionnaire each of them using a four-point ordinal scoring system. For the summary index the scores were standardized from 1 to 40, so that higher scores indicate higher depression.

  5. QUIP-RS sub-scores

    Time frame: at 4 weeks

    Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease - Rating Scale Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the fourth weeks under clonidine.

    It is a self-administered questionnaire. For the summary index the scores were standardized from 1 to 112, so that higher scores indicate higher Impulse control disorder. The sub score are standardized between 0 and 16.

  6. QUIP-RS total score

    Time frame: at 4 and 8 weeks

    Evolution of QUIP-RS total score and sub-scores Diminution of impulse control disorder severity on total score of the QUIP-RS between the first visit, the fourth and the eighth weeks under clonidine.

    It is a self-administered questionnaire. For the summary index the scores were standardized from 1 to 112, so that higher scores indicate higher Impulse control disorder.

  7. PDQ 39 scale (Parkinson Disease Quotation)

    Time frame: at 4 and 8 weeks

    It is a self-administered questionnaire comprised of 39 questions, each of them using a five-point ordinal scoring system, from which a single summary index can be calculated. For the summary index the scores were standardized from 0 to 100, so that higher scores indicate poorer quality of life.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial

Acronym: ID-CLO

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jun 11, 2018
Registry last updated
Sep 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.